A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...
In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic ...
TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic ...
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...
The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David ...
CML is a complex disease and according to Mauro, decision-making often depends on the stage at diagnosis. He explains that it is crucial to carefully assess both the disease and the patient's overall ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback